CG Oncology Joins the 7 Trillion Club with Promising Bladder Cancer Drug

CG Oncology Inc. (NASDAQ: CGON) closed at $61.08 on the Nasdaq on June 17, up 1.08%, bringing its market capitalization to about $5.39 billion (approximately KRW 7.4 trillion). That represents a one-day market cap gain of roughly $58.8 million (around KRW 80 billion), and trading volume of approximately 2.04 million shares slightly exceeded recent averages.

According to its SEC filing, board member James Mulay sold about $118,000 (roughly KRW 160 million) worth of company shares on June 15, signaling insider profit-taking. Since early May—when CG Oncology reported first-quarter results along with updated clinical data for its lead non–muscle invasive bladder cancer candidate—major brokerages have maintained buy ratings and raised price targets into the $80 range.

CG Oncology is a clinical-stage biotech company developing the intravesical tumor-targeted antiviral immunotherapy CretoStimogen Grenadenorepvec for non–muscle invasive bladder cancer, with a focus on expanding treatment options via bladder instillation.